-
Sanofi-aventis and its employees Donate to Tohoku Pacific Earthquake Relief Fund
-
Sanofi-aventis signs New Agreement with the World Health Organization (WHO) to fight Neglected Tropical Diseases
-
Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology in Diabetes and Related Disorders
-
”Svensk cancervård är inte rättvis”
-
Sanofi-aventis appoints Dr. Elias Zerhouni, President, Global Research & Development
-
Resilient sales and business EPS in Q3 2010
-
Sanofi-aventis Establishes Research Collaboration with Harvard University
-
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
-
Jevtana® Improves Survival in Advanced Prostate Cancer Patients
-
Once-Daily Lixisenatide in Combination with Basal Insulin Demonstrates Significant Improvement in Glucose Control
-
Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
-
Nya europeiska riktlinjer för behandling av förmaksflimmer presenterades igår
Visa mer
Loading...